换一批
换一批A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
作者：
主题词
腺嘌呤(Adenine);投药, 口服(Administration, Oral);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);B-淋巴细胞(B-Lymphocytes);细胞色素P-450 CYP3A(Cytochrome P-450 CYP3A);腹泻(Diarrhea);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);药物相互作用(Drug Interactions);红霉素(Erythromycin);女(雌)性(Female);血液肿瘤(Hematologic Neoplasms);人类(Humans);男(雄)性(Male);中年人(Middle Aged);中性粒细胞减少(Neutropenia);哌啶类(Piperidines);多态性, 单核苷酸(Polymorphism, Single Nucleotide);吡唑类(Pyrazoles);嘧啶类(Pyrimidines)
DOI
10.1080/10428194.2018.1460474
PMID
29846137
发布时间
2021-12-04
- 浏览17
Leukemia & lymphoma
2888-2895页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
